-
3 days ago | 
targetedonc.com | Jordyn Sava
The combination of sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) significantly improved progression-free survival (PFS) compared with pembrolizumab and chemotherapy when used for the treatment of patients with inoperable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥ 10), meeting the primary end point of the phase 3 ASCENT-04/KEYNOTE-D19 trial (NCT05382286).1 Topline results from the ASCENT-04/KEYNOTE-D19 study also...
-
6 days ago | 
targetedonc.com | Jordyn Sava
For patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) progressing after osimertinib (Tagrisso) and chemotherapy, the PALOMA-3 trial (NCT05388669) compared subcutaneous (SC) amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) to the intravenous (IV) regimen.
-
6 days ago | 
targetedonc.com | Jordyn Sava
Preliminary results from a phase 2, open-label trial (NCT03328026) indicate a potential survival benefit with the combination of Bria-IMT (SV-BR-1-GM), an off-the-shelf, targeted, cell-based immunotherapy, and immune checkpoint inhibition in patients with heavily pretreated metastatic hormone receptor-positive (HR+) breast cancer.1The study enrolled a cohort of patients with heavily pretreated HR+ metastatic breast cancer (n = 25) who had received a median of 6 prior lines of systemic therapy.
-
1 week ago | 
targetedonc.com | Jordyn Sava
The FDA has cleared the investigational new drug (IND) application for CLD-201 for the treatment of adult patients with solid tumors. CLD-201 is an investigational, allogeneic stem cell-based immunotherapy. Preclinical findings support this IND for the treatment of solid tumors, including breast cancer, head and neck cancer, and soft tissue sarcoma.
-
1 week ago | 
targetedonc.com | Jordyn Sava
Treatment with TLX101 (131I-iodofalan) was well tolerated and showed encouraging efficacy data when used for the treatment of patients with recurrent high-grade glioma, including glioblastoma, according to preliminary results from the phase 2 IPAX-Linz study.1The median overall survival (OS) in the IPAX-Linz trial was 12.4 months from the initiation of treatment with TLX101, and the median OS from initial diagnosis was 32.2 months.
-
1 week ago | 
targetedonc.com | Jordyn Sava
JNJ-1900 (NBTXR3) shows potential as an innovative approach to enhance local tumor control without escalating systemic toxicity across solid tumors, including lung cancer, according to preliminary findings from an ongoing phase 1 study (NCT03589339) presented at the 2025 European Lung Cancer Congress (ELCC).1This novel radioenhancer, composed of functionalized hafnium oxide nanoparticles, is designed to amplify the effectiveness of radiation therapy.
-
1 week ago | 
targetedonc.com | Jordyn Sava
Combination therapy with the MET tyrosine kinase inhibitor savolitinib plus osimertinib (Tagrisso) led to high and durable response rates and was well tolerated for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) and MET-overexpression or -amplification following progressive disease, according to data from the phase 2 SAVANNAH trial (NCT03778229) presented at the 2025 European Lung Cancer Congress.1 Among patients treated with the combination (n = 80),...
-
1 week ago | 
targetedonc.com | Jordyn Sava
SGX301 (HyBryte) continues to show promise in early-stage cutaneous T-cell lymphoma (CTCL), with interim results from an extended treatment study titled FLASH2 (NCT06470451) revealing a 75% "treatment success" rate after 18 weeks.1Interim data from the first 9 enrolled patients, with complete week 18 data available for 8 of them, reveal encouraging outcomes.
-
1 week ago | 
targetedonc.com | Jordyn Sava
A successful Type D meeting between the FDA and IDEAYA Biosciences discussed the design of a phase 3 registrational trial evaluating darovasertib for primary uveal melanoma. Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed as a neoadjuvant therapy for primary uveal melanoma. The planned phase 3 trial will evaluate the safety and efficacy of neoadjuvant darovasertib in patients with primary uveal melanoma.
-
1 week ago | 
targetedonc.com | Jordyn Sava
A phase 1/2 trial evaluating KSQ-004EX, a novel CRISPR-engineered tumor infiltrating lymphocyte (eTIL) therapy, has dosed its first patient with an advanced solid tumor.1This first patient was enrolled by Rodabe Amaria, MD, professor of melanoma medical oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center. “The promise of TIL therapy remains high, but current approaches fall short of addressing the needs of most patients with solid tumors.
